// App-Quantinova.ai

PB1477 : CATEGORIZED HEMATOLOGIC RESPONSE TO PEGCETACOPLAN VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: POST HOC ANALYSIS OF PEGASUS PHASE 3 RANDOMIZED TRIAL DATA

Researchers

Presenter

  • Antonio Risitano

Principal Investigators

  • Ilene C. Weitz

  • Carlos M. de Castro

  • Jean-Jacques Kiladjian

  • Morag Griffin

  • Hisakazu Nishimori

  • Mohammed Al-Adhami

  • Crystal Chen

  • Scott Baver

  • Regis Peffault de Latour

Medical Centers

  • Centre -Investigations Cliniques, Hopital Saint-Louis, Paris, France

  • Duke University, Durham, North Carolina, United States

  • Hematology and BMT Unit,AORN San Giuseppe Moscati,Avellino,Italy

  • Assistance Publique-Hôpitaux de Paris, University Paris 7, Paris, France

  • French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Assistance Publique – Hôpitaux de Paris, Université de Paris, Paris, France

  • Department of Obstetrics and Gynecology, Tokai Univeresity Hospital, Kanagawa, Japan

  • Apellis Pharmaceuticals, Inc.,Waltham,United States

  • Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

  • Jane Anne Nohl Division of Hematology,Keck-USC School of Medicine,Los Angeles, CA,United States

Locations

  • France

  • United States

  • Italy

  • United Kingdom

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Anemia

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

  • Immunol

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03500549

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved